Leukotuximab

Drug Profile

Leukotuximab

Alternative Names: Anti-JL1 monoclonal antibody; ART-140; DNP-001; EGX-040; EGX-140; SSS-19

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Seoul
  • Developer 3SBio; Arana Therapeutics; DiNonA
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action JL1 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Leukaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Leukaemia in South Korea (Parenteral, Injection)
  • 12 May 2016 Preclinical trials in Leukaemia in China (Parenteral)
  • 13 Aug 2014 No development reported - Preclinical for Leukaemia in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top